MSC2156119J

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Conditions

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Trial Timeline

Nov 30, 2009 → Oct 31, 2015

NCT ID

NCT01014936

About MSC2156119J

MSC2156119J is a phase 1 stage product being developed by Merck for Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available. The current trial status is completed. This product is registered under clinical trial identifier NCT01014936. Target conditions include Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01832506	Phase 1	Completed	Apr 30, 2013	Oct 31, 2014	Solid Tumors
NCT01014936	Phase 1	Completed	Nov 30, 2009	Oct 31, 2015	Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Competing Products

20 competing products in Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

See all competitors

Product	Company	Stage	Hype Score
R744 + R744	Chugai Pharmaceutical	Phase 3	77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo	Chugai Pharmaceutical	Phase 3	77
R744 + Epoetin beta	Chugai Pharmaceutical	Phase 3	77
R744 + R744	Chugai Pharmaceutical	Phase 3	77
R744 + R744	Chugai Pharmaceutical	Phase 3	77
R744	Chugai Pharmaceutical	Phase 3	77
PLX3397 + Temozolomide	Daiichi Sankyo	Phase 1/2	41
FK949E	Astellas Pharma	Phase 1	33
roxadustat	Astellas Pharma	Phase 3	77
roxadustat	Astellas Pharma	Phase 3	77
Roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	77
ASP8825	Astellas Pharma	Phase 1	33
ASP015K	Astellas Pharma	Phase 1	33
ASP7991	Astellas Pharma	Phase 1	33
Roxadustat + Epoetin Alfa	Astellas Pharma	Phase 3	77
ATG-F	Astellas Pharma	Approved	85
Celecoxib	Astellas Pharma	Pre-clinical	23
roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	77
roxadustat	Astellas Pharma	Phase 3	77
FK949E	Astellas Pharma	Phase 1	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved